PIPELINE
Developing a pipeline of next level Nanobody® treatments for Inflammatory Diseases

The investigational Nanobody® Sonelokimab has been assessed in a randomized, placebo-controlled, Phase 2b study in 313 patients with moderate to severe plaque-type psoriasis. Sonelokimab demonstrated a rapid and durable high level clinical response (Investigator Global Assessment of Clear or Almost Clear [IGA 0/1], Psoriasis Area and Severity Index [PASI] 90/100) in patients with moderate to severe plaque-type psoriasis, with no unexpected safety findings. The study highlights the promise of Sonelokimab in a number of chronic inflammatory diseases where IL-17A and IL-17F play a key role such as psoriasis, hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis.
References: Papp KA, et al. Lancet. 2021; 397:1564-1575